1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
    Meeting Abstract

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Meeting Abstract

    Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Molecular correlates differentiate response to atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Rini, B. I.; Huseni, M.; Atkins, M. B.; McDermott, D. F.; Powles, T. B.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; Fan, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Meeting Abstract

    Javle, M.; Kelley, R. K.; Roychowdhury, S.; Weiss, K. H.; Abou-Alfa, G. K.; Macarulla, T.; Sadeghi, S.; Waldschmidt, D.; Zhu, A. X.; Goyal, L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Penkov, K.; Haanen, J. B. A. G.; Rini, B. I.; Albiges, L.; Campbell, M. T.; Kollmannsberger, C. K.; Negrier, S.; Uemura, M.; Lee, J. L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950)
    Meeting Abstract

    Gounder, M.; Schöffski, P.; Villalobos, V.; Cote, G.; Chugh, R.; Chen, T. W. W.; Jahan, T.; Loggers, E. T.; Italiano, A.; Gupta, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib
    Meeting Abstract

    George, S.; Bauer, S.; Jones, R. L.; Serrano, C.; von Mehren, M.; Kang, Y. K.; Schöffski, P.; Cassier, P.; Eskens, F. A.; Mir, O.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • VOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)
    Meeting Abstract

    Bauer, S.; George, S.; Kang, Y. K.; Tap, W. D.; Zhou, T.; Picazio, N.; Boral, A. L.; Heinrich, M.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study
    Meeting Abstract

    Di Meglio, A.; El-Mouhebb, M.; Michiels, S.; Jones, L.; Annonay, M.; Zingarello, A.; Matias, M.; Everhard, S.; Martin, A. L.; Arveux, P.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
    Meeting Abstract

    Garon, E. B.; Wong, D. J.; Schneider, J. G.; Aljumaily, R.; Korn, W. M.; Patel, M. R.; Autio, K. A.; Papadopoulos, K. P.; Naing, A.; Gabrail, N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save